Immunomodulation in COVID-19

---

Review Article

Author Details : Sirshendu Pal*, Rupsha Dutta

Volume : 7, Issue : 4, Year : 2022

Article Page : 151-153

https://doi.org/10.18231/j.ijirm.2022.034

Suggest article by email

Get Permission

---

Abstract

Immunology forms the basis for effective treatment strategies and production of vaccines. In COVID 19 immune insufficiency may increase viral replication while uncontrolled immunity may result in tissue damage. The angiotensin converting enzyme receptors on alveolar type 2 cells of lungs act as target cells are the sites of Corona virus attack. These cells through cytokines or interferons initiate an early local response which may control the infection. However, in COVID-19 this interferon response can be subdued or lagging which may allow the COVID virus to escape detection by the innate immunity or depress the downstream reaction leading to unchecked SARS-COV-2 replication. The suppression of host responses leads to increase in pro-inflammatory cytokines and the resulting inflammatory damage leads to a release of suppressive cytokines as a counter regulatory response. This is the cytokine storm. Thus, immuneregulatory treatments that may succeed are the ones that are in real time tuned to the subject's immunophenotype, where immunosuppression may be helpful at some points while immune-stimulation in others.
 

Keywords: Angiotensin converting enzyme, COVID- 19, Cytokines.

How to cite : Pal S, Dutta R, Immunomodulation in COVID-19. IP Indian J Immunol Respir Med 2022;7(4):151-153

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.